Clinically reviewed by Dr. Sarah Boss, MD
Zulresso's US approval was withdrawn effective April 14, 2025 after the manufacturer reported it was no longer marketed. Historical treatment required monitored infusion because of excessive sedation and loss of consciousness. Postpartum psychosis or immediate danger to parent or baby requires emergency assessment.
Brexanolone was the active medicine in Zulresso, an intravenous treatment developed specifically for postpartum depression. This is now a historical product profile, not a current treatment offer. The FDA withdrew Zulresso’s US approval effective April 14, 2025 after the manufacturer stated that it was no longer marketed and requested withdrawal. People may still encounter older websites, research reports and medical records describing it, so understanding both its history and present regulatory status is important. [1]
Current status: read older information carefully
The official withdrawal notice records the manufacturer’s request and the end of marketing. It does not establish that a new safety finding was the reason for withdrawal. Nor does an older approval announcement demonstrate that the product remains routinely available. The notice allowed remaining inventory to be dispensed until depleted or expired, but this narrow provision should not be interpreted as evidence of current supply. [1]
Ask a clinician or pharmacist to verify the current product and jurisdiction before relying on an old description. This page does not identify a supplier or suggest obtaining an unapproved substitute. A directory entry can be useful for understanding treatment history without implying that the medicine is presently prescribed or supplied by Cogniful.
What brexanolone was designed to treat
Brexanolone was developed for postpartum depression, not for ordinary tiredness after childbirth or every mood symptom during pregnancy. Perinatal depression can involve persistent sadness, loss of interest, anxiety, guilt, concentration difficulties and impaired daily functioning. It is a treatable illness, not evidence that a parent lacks commitment or has failed. Assessment should consider the full symptom pattern and immediate safety. [2]
When discussing a historical treatment, describe when symptoms began, how they affected life and which other interventions were tried. A past diagnosis should not be assumed to explain every current difficulty. New symptoms may require a fresh assessment, particularly when there are episodes of unusually elevated mood, severe confusion or changes in perception.
Neurosteroids and the GABA system
Brexanolone is a formulation of allopregnanolone, a neuroactive steroid that modulates GABA-A receptors. Its development followed research into biological changes around pregnancy and postpartum mood disorders. This mechanism differs from that of an SSRI antidepressant. It does not prove that every person’s depression is caused by one hormone level or that measuring that level can select treatment reliably. [3]
A mechanism helps explain why a medicine was studied, but it is not a substitute for clinical evidence. Ask how the research population compares with the person seeking care and what outcomes were measured. Biological explanations should support understanding without oversimplifying the effects of sleep, relationships, previous mental illness and practical support.
What the clinical studies showed
Two randomized, double-blind, placebo-controlled phase 3 trials evaluated brexanolone in women with moderate or severe postpartum depression. They found greater short-term improvement on a depression rating scale with brexanolone than with placebo. The controlled treatment and follow-up conditions matter. These findings did not establish a permanent cure, universal response or an indication for every depressive or anxiety disorder. [4]
Research should be read with attention to timing, eligibility and follow-up. A symptom score at the end of an infusion is not the whole recovery story. Functioning at home, ongoing mood symptoms, infant care and later recurrence also need clinical attention. A person who improved temporarily but later needed further care did not necessarily receive ineffective treatment or fail to use it correctly.
Why treatment required a monitored infusion
Historical administration involved a continuous intravenous infusion over approximately 60 hours in a medical facility. Excessive sedation and sudden loss of consciousness were major safety concerns. Monitoring, trained staff and help with interactions involving children were therefore integral to the treatment, not optional comforts. Older patient information describes these precautions but should not be read as evidence of current availability. [5]
The infusion was not a home injection, a take-home sleep medicine or a product that could be substituted with another GABA-related drug. A historical record should identify the actual medicine and setting. If a current provider proposes something with a similar description, ask whether it is the same active substance, an approved product or an investigational or compounded preparation.
Side effects and medication interactions
Historical adverse effects included sleepiness, dizziness, dry mouth and flushing, with loss of consciousness as a particularly important risk. Other sedating medicines, including opioids and benzodiazepines, required review. A prior reaction should remain part of the person’s medication history even though the product is no longer routinely marketed. Record what happened rather than labeling every unwanted effect as an allergy. [5]
For future treatment decisions, provide discharge records and the names of other medicines used during the admission. This allows the clinician to consider whether sedation reflected brexanolone, another medicine, the combination or an unrelated problem. The distinction can influence subsequent prescribing without requiring the patient to determine the cause alone.
Brexanolone and zuranolone are different medicines
Zuranolone, marketed as Zurzuvae, is an oral neuroactive steroid treatment with its own evidence, authorization and instructions. It is not simply a capsule version that can be substituted for an old brexanolone regimen. The FDA approved oral zuranolone for adult postpartum depression in 2023, and its treatment course and safety requirements differ from a monitored intravenous infusion. [6]
The zuranolone profile explains that separate medicine. A clinician should also discuss established antidepressant and psychological-treatment options where appropriate. The disappearance of one product does not mean that postpartum depression is untreatable or that only a closely related medicine can help.
Current care after an unavailable treatment
When a previously helpful treatment is unavailable, bring a clear account of what improved, how quickly it changed and how long the benefit lasted. Include other treatments taken at the same time and any adverse effects. This history is more useful than asking for an identical experience without explaining the clinical outcome.
Ask the treating team to compare currently available options, including the evidence for your circumstances, monitoring requirements and practical demands. The discussion should include breastfeeding, other medicines, previous bipolar symptoms and available support. A change in product availability should lead to a coordinated review, not an unsupported attempt to source a similar substance online.
Breastfeeding and infant-care questions
Breastfeeding decisions during psychiatric treatment should be individualized using the actual medicine’s current information. Historical lactation data for brexanolone should not be copied onto another neurosteroid or used to assume that a replacement is safe. Ask the maternity and prescribing teams to explain the evidence, uncertainty and feeding options without making the parent feel that treatment and good parenting are incompatible.
Practical support also matters. Clarify who can help with nighttime care, transport and appointments if a new treatment causes sedation or requires attendance at a clinic. A plan that assumes support which is not available needs revision. The parent’s preferences and the baby’s needs should both remain visible in the discussion.
Dependence, withdrawal and detox terminology
Historical patient information warned that brexanolone could be habit-forming. Its supervised infusion protocol should not be confused with unsupervised repeated use of sedating substances. There is no established role here for a self-directed alcohol, benzodiazepine or opioid detox. Shared activity at GABA-related pathways does not make medicines interchangeable. [5]
If postpartum symptoms coexist with alcohol or other substance dependence, both concerns need assessment. Do not abruptly stop a regularly used sedative in an attempt to prepare for a psychiatric treatment. The team should plan the order of care, immediate safety and continuing support rather than treating detox as a prerequisite that must be managed alone.
Postpartum psychosis is an emergency
Postpartum psychosis can involve hallucinations, delusions, mania, paranoia and severe confusion. It requires immediate medical assessment and often hospital care. It is not the same as uncomplicated postpartum depression and should not be managed by waiting for access to a particular antidepressant. Immediate danger to the parent or baby also requires emergency help. [2]
Family members can help by describing what changed and when, while avoiding arguments about whether an unusual belief is true. Keep the focus on obtaining care and maintaining safety. A medication directory, routine clinic message or planned consultation is not an emergency-response service.
Continuing care after initial improvement
Recovery planning should include the next clinician, follow-up appointments, psychological support and a way to report recurrence. Ask how symptoms will be reviewed beyond the first treatment course and who coordinates the plan with primary care and maternity services. Improvement does not make practical pressures disappear, and continuing support should not be withdrawn solely because a rating scale improves.
Choose a few meaningful indicators to discuss: sleep when there is an opportunity to rest, ability to enjoy ordinary activities, concentration and confidence in managing the day. These observations support clinical review without becoming a test of parenting ability. A trusted person may help record changes with the patient’s consent.
Frequently asked questions
Is Zulresso still a routine US treatment option?
No. Its FDA approval was withdrawn effective April 14, 2025 after the manufacturer reported that it was no longer marketed. Older descriptions of approval should be read alongside that later notice.
Was withdrawal of approval proof that it was ineffective?
No. The notice does not make that claim. Clinical-trial evidence and a product’s marketing status answer different questions. Neither should be misrepresented to explain the other.
Why retain a page about a historical medicine?
Patients and clinicians may encounter the name in old records or research. A clearly labeled historical guide can explain those references while directing current decisions toward verified, available care rather than implying an offer to supply the product.
